Psilocybin Misconceptions: Case Reports, Blinding, and Headline Inflation

Corrections for reading psychedelic-therapeutics coverage, kept out of the reference chunks. ## About the trial evidence **Double-blind does not mean blinded here.** Participants in psilocybin trials correctly identify their arm far above chance, because the experience is unmistakable. The measured difference between arms therefore includes an expectancy component of unknown size — inflating the drug arm and deflating placebo simultaneously. See Functional Unblinding: Why Psychedelic Trials Cannot Fully Blind. **"Statistically significant" is not "large".** The Phase 3 MADRS differences are around 3–4 points on a 0–60 scale — statistically strong, clinically modest. In COMP006, 39% of the 25 mg arm showed a clinically meaningful reduction, meaning most participants did not. **COMP006 compared 25 mg against 1 mg, not against placebo.** This is routinely dropped in summaries. It is a dose-comparison result, which answers a different question than drug-versus-nothing. **Not every trial succeeded.** The EPISODE trial missed its primary endpoint. Coverage tends to aggregate the positive readouts. **Expectancy predicts outcome.** Pre-treatment expectancy scores correlate with response, which is a direct measurement of the problem rather than a theoretical worry. ## About neurodegeneration claims **There is no psilocybin trial in Huntington's disease.** What exists is a proposed protocol published in an undergraduate research-protocol journal, plus review-level speculation. A protocol is a plan, not a result. **Search false positive worth knowing:** headlines about "new hope for Huntington's disease" are usually about **AMT-130 gene therapy** — an AAV delivering microRNA to silence mutant HTT — not psychedelics. The two get conflated easily and the conflation badly misrepresents the field. **The Alzheimer's material is a single case report.** One patient, no neuroimaging, no standardised cognitive scales, no control, improvements the authors call transient and explicitly not disease reversal. It is being circulated as though it were a trial. It is n = 1. **The ongoing MCI/early-Alzheimer's trial targets depression, not dementia pathology.** A positive result would say something about treating depression in that population, not about slowing the disease. **The mechanism has a known weak point.** Psilocybin's pro-plasticity effect works through 5-HT2A, which is dense in neocortex — while the hippocampus, where you would most want the effect for dementia, is comparatively richer in 5-HT1A. ## About the aging result **Mouse lifespan extension is among the most replication-fragile findings in biology**, highly sensitive to strain, diet, housing, sex, and control husbandry. The Emory psilocin result is an interesting preclinical finding awaiting independent replication, not evidence of a human longevity effect. Treatment starting at 19 months also tests late-life intervention specifically, and increased survival from that point is not the same as extended maximum lifespan. ## About the framing generally **Psilocybin is a pro-drug; psilocin is the active compound.** Papers refer to whichever is relevant, and the two are not interchangeable in mechanism discussions. **Safety is not zero.** It is contraindicated where there is psychosis or bipolar risk, some trials have logged transient suicidality in a minority of participants, and administration requires hours of supervision. "Natural" and "non-addictive" do not mean risk-free. **The therapy wrapper is a confound, not a detail.** Dosing sessions are embedded in preparation and integration psychotherapy with substantial contact time. Separating drug effect from ritual, attention and therapeutic alliance is an unsolved design problem, not a refinement. **The field selects for enthusiasts.** Psychedelic research attracts researchers who believe in it, which is a reason to weight null results and methodological critiques more heavily than usual rather than less.